Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Current Liabilities: 2013-2025

Historic Total Current Liabilities for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $37.4 million.

  • Theravance Biopharma's Total Current Liabilities rose 59.62% to $37.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.4 million, marking a year-over-year increase of 59.62%. This contributed to the annual value of $32.1 million for FY2024, which is 29.55% up from last year.
  • Theravance Biopharma's Total Current Liabilities amounted to $37.4 million in Q3 2025, which was down 31.53% from $54.6 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Total Current Liabilities peaked at $142.1 million during Q3 2022, and registered a low of $21.7 million during Q1 2024.
  • Moreover, its 3-year median value for Total Current Liabilities was $25.4 million (2023), whereas its average is $29.5 million.
  • In the last 5 years, Theravance Biopharma's Total Current Liabilities slumped by 82.15% in 2023 and then surged by 138.09% in 2025.
  • Over the past 5 years, Theravance Biopharma's Total Current Liabilities (Quarterly) stood at $58.6 million in 2021, then slumped by 50.99% to $28.7 million in 2022, then dropped by 13.75% to $24.8 million in 2023, then grew by 29.55% to $32.1 million in 2024, then soared by 59.62% to $37.4 million in 2025.
  • Its last three reported values are $37.4 million in Q3 2025, $54.6 million for Q2 2025, and $31.5 million during Q1 2025.